Equities

Tivic Health Systems Inc

Z2G0:BER

Tivic Health Systems Inc

Actions
  • Price (EUR)0.00
  • Today's Change0.00 / --
  • Shares traded-1.00
  • 1 Year change-100.00%
  • Beta--
Data delayed at least 15 minutes, as of Aug 24 2023.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Tivic Health Systems, Inc. is a commercial-stage health tech company advancing the field of bioelectronic medicine. The Company’s patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Its non-invasive and targeted approach to the treatment of inflammatory chronic health conditions is intended to give consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. The Company’s first commercial product, ClearUP, is an FDA approved handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and available through online retailers and commercial distributors. ClearUP is sold in the U.S. directly to consumers on various platforms and through reseller channels. The Company is also focused on its intellectual property (IP) portfolio and research programs related to vagus nerve stimulation to expand its applications in non-invasive bioelectronic medicine.

  • Revenue in USD (TTM)1.13m
  • Net income in USD-7.61m
  • Incorporated2021
  • Employees9.00
  • Location
    Tivic Health Systems Inc25821 Industrial Blvd, Ste 100HAYWARD 94545United StatesUSA
  • Fax+1 (302) 636-5454
  • Websitehttps://tivichealth.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.